The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression

Removal of autologous activated CD4-positive T lymphocytes also results in increased colony-forming units in patients with low and intermediate-1 risk myelodysplastic syndromes

(2010) Zhang Zheng et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

In vitro deprivation of CD8+CD57+T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome

(2010) Zhang Zheng et al.   EXPERIMENTAL HEMATOLOGY

Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions

(2010) Elaine M. Sloand et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions

(2009) P. Valent et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Myelodysplastic Syndromes

(2009) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnosis of unknown nonhematological tumors by bone marrow biopsy: a retrospective analysis of 10,112 samples

(2008) Li Xiao et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy

(2008) Elaine M. Sloand et al.   JOURNAL OF CLINICAL ONCOLOGY

Deviation of type I and type II T cells and its negative effect on hematopoiesis in myelodysplastic syndrome

(2007) L. WU et al.   International Journal of Laboratory Hematology